Beijing GoBroad Healthcare Group Hospitals

GoBroad Healthcare Group Hospitals (GHG) is a pioneer of the research-oriented hospital mode in China specialized on Hematology and Oncology, we currently operates 8 hospitals in Beijing, Shanghai and Guangzhou, with a combined open bed capacity of nearly 1500 beds, and mainly focuses on clinical treatment, clinical research, reference laboratories and information technology. GHG has joined hands with a group of top-notch medical experts with rich clinical experience and scientific research backgrounds to create a unique “Academic Research Organization (ARO)”. Our organizational strategy is to build an innovative medical ecosystem of “clinical discovery-basic research-industrial transformation-clinical application” and improve the efficiency and quality of development in the biomedicine industry. We have always adhered to the value of “The Needs of the Patient Come First” and is committed to building a clinical-oriented, innovative medical technology platform. With the mission and vision of pursuing excellence in the diagnosis and treatment of diseases, employing technological innovation and pursuing the hope of diseases, we are progressively building our hospital group into several leading hematology and cancer research hospitals. A research-oriented hospital is an important carrier of the ARO mode, the GHG focuses on innovative and research-active specialties such as solid tumors, hematological diseases and brain science. GHG has established professional service fields, including a Phase I clinical trial ward, a central laboratory, and an early-stage clinical research center, while providing clinical pharmacology, medicine, and statistical analysis. We are a national leader in a number of cancer therapies, such as adoptive cell therapy, immunotherapy and targeted therapy. In particular, our team of experts has extensive experience in chimeric antigen receptor T cell immunotherapy, also known as CAR-T Therapy, they have published over 70 academic papers globally and delivered more than 100 presentations at international conferences such as ASH, EHA, and ASCO. To date, we have successfully treated nearly 5,000 patients using CAR-T cell therapy, helped over 1000 patients from overseas, making us the most experienced CAR-T treatment center in China. In addition, we are equipped with a professional healthcare multidisciplinary team to provide comprehensive and personalized integrated medical care in pursuit of more accurate diagnosis and more humanistic patient services.  With the medical mission of treating severe diseases that have proved to be difficult to treat, GHG has brought more treatment options and hope to the vast number of patients with severe diseases that are difficult to treat. With the scientific research mission of promoting medical innovation, GHG has served hundreds of innovative pharmaceutical companies in a large number of innovative drug clinical trials. Advances in medicine are stemmed from the idea that encourages innovation, and improvements in innovation are derived from the practice of embracing medicine.

Beijing, Shanghai, Guangzhou - Beijing, Shanghai, Guangzhou - China

Short info:

Send Request


GoBroad Healthcare Group Hospitals (GHG) is a pioneer of the research-oriented hospital mode in China specialized on Hematology and Oncology, we currently operates 8 hospitals in Beijing, Shanghai and Guangzhou, with a combined open bed capacity of nearly 1500 beds, and mainly focuses on clinical treatment, clinical research, reference laboratories and information technology. GHG has joined hands with a group of top-notch medical experts with rich clinical experience and scientific research backgrounds to create a unique “Academic Research Organization (ARO)”. Our organizational strategy is to build an innovative medical ecosystem of “clinical discovery-basic research-industrial transformation-clinical application” and improve the efficiency and quality of development in the biomedicine industry.

We have always adhered to the value of “The Needs of the Patient Come First” and is committed to building a clinical-oriented, innovative medical technology platform. With the mission and vision of pursuing excellence in the diagnosis and treatment of diseases, employing technological innovation and pursuing the hope of diseases, we are progressively building our hospital group into several leading hematology and cancer research hospitals.

A research-oriented hospital is an important carrier of the ARO mode, the GHG focuses on innovative and research-active specialties such as solid tumors, hematological diseases and brain science. GHG has established professional service fields, including a Phase I clinical trial ward, a central laboratory, and an early-stage clinical research center, while providing clinical pharmacology, medicine, and statistical analysis. We are a national leader in a number of cancer therapies, such as adoptive cell therapy, immunotherapy and targeted therapy. In particular, our team of experts has extensive experience in chimeric antigen receptor T cell immunotherapy, also known as CAR-T Therapy, they have published over 70 academic papers globally and delivered more than 100 presentations at international conferences such as ASH, EHA, and ASCO. To date, we have successfully treated nearly 5,000 patients using CAR-T cell therapy, helped over 1000 patients from overseas, making us the most experienced CAR-T treatment center in China. In addition, we are equipped with a professional healthcare multidisciplinary team to provide comprehensive and personalized integrated medical care in pursuit of more accurate diagnosis and more humanistic patient services. 

With the medical mission of treating severe diseases that have proved to be difficult to treat, GHG has brought more treatment options and hope to the vast number of patients with severe diseases that are difficult to treat. With the scientific research mission of promoting medical innovation, GHG has served hundreds of innovative pharmaceutical companies in a large number of innovative drug clinical trials. Advances in medicine are stemmed from the idea that encourages innovation, and improvements in innovation are derived from the practice of embracing medicine.